Lilly trumpets Cymbalta as arthritis med

Eli Lilly's Cymbalta might make the leap from psychiatric med to arthritis treatment. The company announced today that a study showed that 59 percent of patients saw their pain cut by 30 percent with Cymbalta, and 47 percent had a 50 percent reduction. That's compared with 45 percent and 29 percent on placebo, respectively. It wouldn't be Cymbalta's first painkilling indication; it's also approved for diabetic nerve pain. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.